Literature DB >> 8076689

Identification and hypotensive activity of proadrenomedullin N-terminal 20 peptide (PAMP).

K Kitamura1, K Kangawa, Y Ishiyama, H Washimine, Y Ichiki, M Kawamoto, N Minamino, H Matsuo, T Eto.   

Abstract

Proadrenomedullin N-terminal 20 peptide (PAMP) is a candidate for a novel biologically active peptide processed from an adrenomedullin precursor. Using a radioimmunoassay for human PAMP, major and minor immunoreactive PAMPs were purified from porcine adrenal medulla and complete amino acid sequences were determined. The major immunoreactive peptide was PAMP itself with an amidated carboxy terminus. The minor one was determined to be PAMP[5-20]. An intravenous bolus injection of human PAMP in anesthetized rats caused a rapid and strong hypotensive effect in a dose dependent manner. The present data indicate that PAMP is an endogenous biologically active peptide which is processed from adrenomedullin precursor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8076689     DOI: 10.1016/0014-5793(94)00810-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

1.  Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification.

Authors:  Habib Bouzina; Göran Rådegran
Journal:  Pulm Circ       Date:  2020-06-15       Impact factor: 3.017

2.  Genetic loss of proadrenomedullin N-terminal 20 peptide (PAMP) in mice is compatible with survival.

Authors:  Brooke C Matson; Manyu Li; Claire E Trincot; Elizabeth S Blakeney; Stephanie L Pierce; Kathleen M Caron
Journal:  Peptides       Date:  2018-12-08       Impact factor: 3.750

Review 3.  Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker?

Authors:  Mihael Potocki; Ronny Ziller; Christian Mueller
Journal:  Curr Heart Fail Rep       Date:  2012-09

Review 4.  Novel neurohumoral factors in congestive heart failure: adrenomedullin.

Authors:  J G Lainchbury
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

5.  Adrenomedullin suppresses fMLP-induced upregulation of CD11b of human neutrophils.

Authors:  Y Saito; C Nakagawa; H Uchida; F Sasaki; H Sakakibara
Journal:  Inflammation       Date:  2001-06       Impact factor: 4.092

Review 6.  Adrenomedullin. Implications for hypertension research.

Authors:  K Kitamura; K Kangawa; H Matsuo; T Eto
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

7.  Proadrenomedullin NH(2)-terminal 20 peptide, a new product of the adrenomedullin gene, inhibits norepinephrine overflow from nerve endings.

Authors:  T Shimosawa; Y Ito; K Ando; K Kitamura; K Kangawa; T Fujita
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

8.  Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP).

Authors:  I B Wilkinson; C M McEniery; K H Bongaerts; H MacCallum; D J Webb; J R Cockcroft
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

9.  Adrenomedullin expression in the human endometrium.

Authors:  J B Laoag-Fernandez; T Otani; T Maruo
Journal:  Endocrine       Date:  2000-02       Impact factor: 3.633

Review 10.  Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.

Authors:  D Bell; B J McDermott
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.